Nelson Vergel
Founder, ExcelMale.com
The Headline
An FDA advisory panel voted to recommend that BPC-157 be allowed back into compounding pharmacies. The vote was 8 to 6, with one abstention. The same panel also voted in favor of KPV, TB-500, and MOTS-c. This does not make these peptides legal tomorrow. It is a recommendation, and the FDA still has to decide what to do with it.
The Setting
The panel is called the Pharmacy Compounding Advisory Committee (PCAC). It met at FDA's White Oak campus in Maryland. The question on the table was whether seven peptides should be added to the "503A Bulks List," which is the list that lets a compounding pharmacy legally make a drug from raw ingredient when that ingredient has no FDA-approved product and no USP monograph behind it. None of the seven currently qualifies any other way.
Day one covered BPC-157, KPV, TB-500, and MOTS-c. Day two covered emideltide (DSIP), epitalon, and Semax.
What FDA's Own Scientists Presented
The agency's career reviewers went first, and they recommended against all seven. They applied a four-part test to each substance: chemical characterization, history of compounding use, evidence of effectiveness, and safety. Their key points in plain terms:
Nobody agrees what the substance actually is. Nominators submitted contradictory information about whether they meant the free base or the acetate salt, which are chemically different with different stability and solubility. Names like "BPC-157" are not official adopted drug names and get used inconsistently across suppliers, so a patient could receive something other than what was intended. An FDA official put it bluntly: Russell Wesdyk of FDA's drug center said there is no way to know what the substance is or will be tomorrow, because the name carries no legal meaning.
The human evidence is thin. For BPC-157, reviewers found one small trial for ulcerative colitis, published only as a decades-old meeting abstract, and no studies at all using the oral, subcutaneous, nasal, or transdermal routes that compounders actually propose. The five BPC-157 studies FDA looked at were short, small, and used doses that appeared exploratory. For KPV, TB-500, and MOTS-c, FDA found no human clinical studies at all.
Injection raises immune concerns. Because these are peptides going into the body by needle or nose, FDA flagged immunogenicity: the risk of the body reacting to the peptide or to impurities and clumped protein from manufacturing. Few of the certificates of analysis submitted included testing for impurities, aggregates, or bacterial endotoxins.
Approved options already exist. For every condition reviewed, including ulcerative colitis and wound healing, FDA pointed to existing approved drugs with established track records.
Substance-specific flags:
What the Industry and Public Presented
The two days included more than 18 hours of discussion and presentations. During public comment, the panel heard from more than two dozen speakers, including doctors, lawyers, and peptide entrepreneurs, nearly all urging wider access.
The central argument was about the gray market. Speakers described patients buying unvetted product online from questionable suppliers. Brigham Buhler, a wellness clinic owner whose clients include Joe Rogan, argued that letting U.S. pharmacies compound peptides would pull Americans away from unverified imports from China and elsewhere, and that people already using these products will keep using them regardless.
Industry groups also told the panel that FDA's review did not include newer scientific data on BPC-157, including human study results submitted ahead of the meeting. FDA staff said they would take that material into account before any final decision.
How the Panel Itself Split
The vote tally reflected an unusual panel composition. More than half a dozen people with peptide industry connections, including doctors, pharmacists, and consultants working in the field, were added before the meeting. FDA overhauled the committee roster in June, and added temporary voting members from academic institutions earlier this week.
Members with academic backgrounds rather than peptide backgrounds mostly voted no.
Voices from each side:
What This Means for You Practically
It is not approval. These are advisory recommendations, not FDA decisions, and they do not make either substance an approved drug product. FDA is not required to follow the advice, though it usually does.
Nothing changes this week. Formally adding these to the list requires new regulations, which take months or years to write. FDA watchers think the more likely near-term move is an interim policy telling pharmacies they will not be targeted for compounding these peptides.
The indication is narrow, the prescribing may not be. BPC-157 was evaluated specifically for ulcerative colitis, not for tendon healing or gut repair generally. But if FDA reclassifies these, clinicians would have discretion to prescribe outside those narrow indications.
503B is separate. This vote concerns 503A pharmacies filling individual prescriptions. Larger outsourcing facilities operate under a different list and a different process.
The quality question stays open. The naming and characterization problem FDA raised is real regardless of how the politics resolve. If you use these compounds, where they come from and whether the pharmacy tests each batch for potency, purity, and sterility matters more than the regulatory headline.
What Happens Next
FDA reviews the votes, the discussion, and the public comments, then makes its own determination on each peptide. Day two votes on emideltide, Semax, and epitalon happened today, July 24. I will cover those results separately.
Look at the analysis I curated recently: List of Peptides and Their Evidence
And this more detailed review: List of Over 65 Peptides, Their Use, and Common Dosages
An FDA advisory panel voted to recommend that BPC-157 be allowed back into compounding pharmacies. The vote was 8 to 6, with one abstention. The same panel also voted in favor of KPV, TB-500, and MOTS-c. This does not make these peptides legal tomorrow. It is a recommendation, and the FDA still has to decide what to do with it.
The Setting
The panel is called the Pharmacy Compounding Advisory Committee (PCAC). It met at FDA's White Oak campus in Maryland. The question on the table was whether seven peptides should be added to the "503A Bulks List," which is the list that lets a compounding pharmacy legally make a drug from raw ingredient when that ingredient has no FDA-approved product and no USP monograph behind it. None of the seven currently qualifies any other way.
Day one covered BPC-157, KPV, TB-500, and MOTS-c. Day two covered emideltide (DSIP), epitalon, and Semax.
What FDA's Own Scientists Presented
The agency's career reviewers went first, and they recommended against all seven. They applied a four-part test to each substance: chemical characterization, history of compounding use, evidence of effectiveness, and safety. Their key points in plain terms:
Nobody agrees what the substance actually is. Nominators submitted contradictory information about whether they meant the free base or the acetate salt, which are chemically different with different stability and solubility. Names like "BPC-157" are not official adopted drug names and get used inconsistently across suppliers, so a patient could receive something other than what was intended. An FDA official put it bluntly: Russell Wesdyk of FDA's drug center said there is no way to know what the substance is or will be tomorrow, because the name carries no legal meaning.
The human evidence is thin. For BPC-157, reviewers found one small trial for ulcerative colitis, published only as a decades-old meeting abstract, and no studies at all using the oral, subcutaneous, nasal, or transdermal routes that compounders actually propose. The five BPC-157 studies FDA looked at were short, small, and used doses that appeared exploratory. For KPV, TB-500, and MOTS-c, FDA found no human clinical studies at all.
Injection raises immune concerns. Because these are peptides going into the body by needle or nose, FDA flagged immunogenicity: the risk of the body reacting to the peptide or to impurities and clumped protein from manufacturing. Few of the certificates of analysis submitted included testing for impurities, aggregates, or bacterial endotoxins.
Approved options already exist. For every condition reviewed, including ulcerative colitis and wound healing, FDA pointed to existing approved drugs with established track records.
Substance-specific flags:
- BPC-157: three adverse event reports tied to compounded injectables, including one patient with shortness of breath and another who developed widespread skin darkening and darkened gums after a blended BPC-157/TB-500 product labeled "research purposes only."
- TB-500: an in vitro study found the intact peptide did not close wounds in cultured cells, though a breakdown product showed modest activity. Also on the WADA banned list.
- MOTS-c: also WADA-prohibited, and FDA found no evidence any outsourcing facility has ever compounded it.
What the Industry and Public Presented
The two days included more than 18 hours of discussion and presentations. During public comment, the panel heard from more than two dozen speakers, including doctors, lawyers, and peptide entrepreneurs, nearly all urging wider access.
The central argument was about the gray market. Speakers described patients buying unvetted product online from questionable suppliers. Brigham Buhler, a wellness clinic owner whose clients include Joe Rogan, argued that letting U.S. pharmacies compound peptides would pull Americans away from unverified imports from China and elsewhere, and that people already using these products will keep using them regardless.
Industry groups also told the panel that FDA's review did not include newer scientific data on BPC-157, including human study results submitted ahead of the meeting. FDA staff said they would take that material into account before any final decision.
How the Panel Itself Split
The vote tally reflected an unusual panel composition. More than half a dozen people with peptide industry connections, including doctors, pharmacists, and consultants working in the field, were added before the meeting. FDA overhauled the committee roster in June, and added temporary voting members from academic institutions earlier this week.
Members with academic backgrounds rather than peptide backgrounds mostly voted no.
Voices from each side:
- David Pope of Xifin Pharmacy Solutions voted yes, saying it was time to return the decision to the patient, physician, and pharmacist.
- Dr. Kris Wusterhausen, who runs a Texas practice advertising hormone and peptide therapy, said that once you see the effects of BPC, you cannot unsee it.
- Dr. Elizabeth Rebello of MD Anderson voted no, saying she was concerned the panel was responding to market-driven demand rather than solid science.
- Other members worried that an official FDA listing would send the public a misleading signal about how limited the evidence is.
What This Means for You Practically
It is not approval. These are advisory recommendations, not FDA decisions, and they do not make either substance an approved drug product. FDA is not required to follow the advice, though it usually does.
Nothing changes this week. Formally adding these to the list requires new regulations, which take months or years to write. FDA watchers think the more likely near-term move is an interim policy telling pharmacies they will not be targeted for compounding these peptides.
The indication is narrow, the prescribing may not be. BPC-157 was evaluated specifically for ulcerative colitis, not for tendon healing or gut repair generally. But if FDA reclassifies these, clinicians would have discretion to prescribe outside those narrow indications.
503B is separate. This vote concerns 503A pharmacies filling individual prescriptions. Larger outsourcing facilities operate under a different list and a different process.
The quality question stays open. The naming and characterization problem FDA raised is real regardless of how the politics resolve. If you use these compounds, where they come from and whether the pharmacy tests each batch for potency, purity, and sterility matters more than the regulatory headline.
What Happens Next
FDA reviews the votes, the discussion, and the public comments, then makes its own determination on each peptide. Day two votes on emideltide, Semax, and epitalon happened today, July 24. I will cover those results separately.
Look at the analysis I curated recently: List of Peptides and Their Evidence
And this more detailed review: List of Over 65 Peptides, Their Use, and Common Dosages
Last edited:
